Ensign Peak Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.87M Sell
257,525
-33,293
-11% -$799K 0.01% 630
2026
Q2
$9.7M Buy
290,818
+284,097
+4,227% +$7.06M 0.02% 444
2026
Q1
$141K Sell
6,721
-243,850
-97% -$5.49M ﹤0.01% 1474
2025
Q4
$5.76M Buy
250,571
+73,150
+41% +$2.41M 0.01% 498
2025
Q3
$5.34M Buy
177,421
+141,350
+392% +$4.24M 0.01% 579
2025
Q2
$1.31M Hold
36,071
– – ﹤0.01% 1091
2025
Q1
$1.31M Buy
36,071
+6,850
+23% +$285K ﹤0.01% 1107
2024
Q4
$1.23M Buy
29,221
+100
+0.3% +$4.96K ﹤0.01% 1195
2024
Q3
$1.62M Hold
29,121
– – ﹤0.01% 1046
2024
Q2
$1.2M Hold
29,121
– – ﹤0.01% 1172
2024
Q1
$1.36M Sell
29,121
-1,469
-5% -$69.3K ﹤0.01% 1129
2023
Q4
$1.46M Hold
30,590
– – ﹤0.01% 1103
2023
Q3
$1.09M Hold
30,590
– – ﹤0.01% 1132
2023
Q2
$1.41M Buy
30,590
+450
+1% +$20.9K ﹤0.01% 1015
2023
Q1
$1.21M Hold
30,140
– – ﹤0.01% 1091
2022
Q4
$1.4M Sell
30,140
-83,849
-74% -$3.3M ﹤0.01% 952
2022
Q3
$4.72M Buy
113,989
+28,675
+34% +$1.47M 0.01% 534
2022
Q2
$5.09M Buy
85,314
+70,614
+480% +$4.35M 0.01% 533
2022
Q1
$1.07M Hold
14,700
– – ﹤0.01% 1157
2021
Q4
$1.24M Buy
+14,700
New +$1.2M ﹤0.01% 1171

Other funds holding RARE

Ensign Peak Advisors's RARE Position: Q3 2026 in Review

Ensign Peak Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 11% in Q3 2026, selling an estimated $799K and leaving 257,525 shares worth $3.87M. The position accounts for 0.01% of the portfolio, ranked #630.

Ensign Peak Advisors first reported a position in RARE in Q4 2021 and has held it in 20 quarters since. The position peaked at $9.7M in Q2 2026. 268 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • Ensign Peak Advisors held 257,525 shares of Ultragenyx Pharmaceutical worth $3.87M as of Q3 2026.
  • Ensign Peak Advisors sold 33,293 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $799K.
  • Ultragenyx Pharmaceutical made up 0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #630 holding.
  • Ensign Peak Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and has held it in 20 quarters since.
  • Ensign Peak Advisors's Ultragenyx Pharmaceutical position peaked at $9.7M in Q2 2026.
  • 268 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.